Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

Journal of Clinical Oncology

Volumn 24, Issue 26, 2006, Pages 4293-4300

  Abou Alfa, Ghassan K ^a   Schwartz, Lawrence ^a   Ricci, Sergio ^a   Amadori, Dino ^a   Santoro, Armando ^a   Figer, Arie ^a   De Greve, Jacques ^a   Douillard, Jean Yves ^a   Lathia, Chetan ^a   Schwartz, Brian ^a   Taylor, Ian ^a   Moscovici, Marius ^a   Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RNA; TUMOR MARKER;

ADULT; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FEMALE; HAND FOOT SKIN REACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SKIN TOXICITY; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS; VOMITING; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PYRIDINES; RNA, NEOPLASM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33749017926     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.3441     Document Type: Article

References (26)

1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80:827-841, 1999
2. McGlynn KA, Tsao L, Hsing AW, et al: International trends and patterns of primary liver cancer. Int J Cancer 94:290-296, 2001
3. El Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750, 1999
4. Llovet JM, Bruix J, Gores GJ: Surgical resection versus transplantation for early hepatocellular carcinoma: Clues for the best strategy. Hepatology 31:1019-1021, 2000
5. Abou-Alfa GK: Current and novel therapeutics for hepatocellular carcinoma. Am Soc Clin Oncol Educational Book, Alexandria, VA, 2004, pp 192-197
6. Huynh H, Nguyen TT, Chow KH, et al: Overexpression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis. BMC Gastroenterol 3:19, 2003
7. Giambartolomei S, Covone F, Levrero M, et al: Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 20:2606-2610, 2001
8. Shimotohno K, Watashi K, Tsuchihara K, et al: Hepatitis C virus and its roles in cell proliferation. J Gastroenterol 37:50-54, 2002 (suppl)
9. Yoshiji H, Kuriyama S, Yoshii J, et al: Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 39:1517-1524, 2004
10. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
11. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972, 2005
12. Pero R, Peto J: Asymptotically efficient rank-invariant test procedures. J R Stat Soc A 135:185-206, 1972
13. Hofmann WK, de Vos S, Elashoff D, et al: Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: A gene-expression study. Lancet 359:481-486, 2002
14. Kurokawa Y, Matoba R, Nagano H, et al: Molecular prediction of response to 5-fluorouracil and interferon-{alpha} combination chemotherapy in advanced hepatocellular carcinoma. Clin Cancer Res 10:6029-6038, 2004
15. Chenivesse X, Franco D, Brechot C: MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J Hepatol 18:168-172, 1993s
16. Soini Y, Virkajarvi N, Raunio H, et al: Expression of P-glycoprotein in hepatocellular carcinoma: A potential marker of prognosis. J Clin Pathol 49:470-473, 1996
17. DeVita VT Jr, Abou-Alfa GK: Therapeutic implications of the new biology. Cancer J 6 Suppl 2:S113-S120, 2000
18. Jiang W, Lu Z, He Y, et al: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3:395-399, 1997
19. Abou-Alfa GK, Morse M: New small molecules for liver tumors, in Clavien P (ed): Malignant Liver Tumors, Current and Emerging Therapies (ed 2). Sudbury, MA, Jones and Bartlett, 2004, pp 307-314
20. Leung TW, Patt YZ, Lau WY, et al: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676-1681, 1999
21. Lee J, Park JO, Kim WS, et al: Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 54:385-390, 2004
22. Yeo W, Mok TS, Zee B, et al: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532-1538, 2005
23. Richly H, Kupsch P, Passage K, et al: Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 42:650-651, 2004
24. DePrimo SE, Wong LM, Khatry DB, et al: Expression profiling of blood samples from an SU5416 phase III metastatic colorectal cancer clinical trial: A novel strategy for biomarker identification. BMC Cancer 3:3, 2003
25. Qin LX, Tang ZY: Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: A review of the literature. J Cancer Res Clin Oncol 130:497-513, 2004
26. Khokhlatchev AV, Canagarajah B, Wilsbacher J, et al: Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 93:605-615, 1998